Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013

Annatina Schnegg-Kaufmann\textsuperscript{a,b,1}, Anita Feller\textsuperscript{c,1}, Helen Baldomero\textsuperscript{d}, Alicia Rovo\textsuperscript{a}, Markus G. Manz\textsuperscript{e}, Michael Gregor\textsuperscript{f}, Anna Efthymiou\textsuperscript{g}, Mario Bargetzi\textsuperscript{h}, Urs Hess\textsuperscript{i}, Olivier Sperti\textsuperscript{i}, Yves Chalandon\textsuperscript{k}, Jakob R. Passweg\textsuperscript{c,d}, Georg Stussi\textsuperscript{i}, Volker Arndt\textsuperscript{c}, Nicolas Bonadies\textsuperscript{a,b,⁎}, the NICER Working Group

\textsuperscript{a} Department of Haematology and Central Haematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland
\textsuperscript{b} Department for BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland
\textsuperscript{c} Foundation National Institute for Cancer Epidemiology and Registration (NICER) c/o University of Zurich, Switzerland
\textsuperscript{d} Divisions of Hematology, Department of Medicine, University Hospital Basel, Switzerland
\textsuperscript{e} Haematology, University and University Hospital Zurich, Switzerland
\textsuperscript{f} Division of Haematology and Central Haematology Laboratory, Cantonal Hospital Lucerne, Switzerland
\textsuperscript{g} Department of Haematology-Onco, Cantonal Hospital Fribourg, Switzerland
\textsuperscript{h} Division of Haematology and Transfusion Medicine, Cantonal Hospital Aarau, Switzerland
\textsuperscript{i} Clinic for Haematology and Oncology, Cantonal Hospital St. Gallen, Switzerland
\textsuperscript{j} Service and Central Laboratory of Haematology, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital, Switzerland
\textsuperscript{k} Department of Oncology, Division of Hematology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland
\textsuperscript{1} Clinic of Haematology, Oncology Institute of Southern Switzerland, Switzerland

ARTICLE INFO

Keywords:
Acute myeloid leukaemia
Epidemiology
Classification
Incidence
Mortality
Survival

ABSTRACT

Acute Myeloid Leukaemia (AML) is a rare and heterogeneous haematological malignancy with increasing incidence in the elderly. We performed a population-based, observational analysis of AML cases reported to the Cantonal Cancer Registries in Switzerland. Data was aggregated by the National Institute for Epidemiology and Cancer Registration and stratified for the two time periods 2001–2007 and 2008–2013. Overall, 2351 new AML cases were registered with a stable age-standardised incidence rate (3.0 [95 CI: 2.8-3.2] per 100,000 person-years). This indicates that our observed raise of annual AML cases (+10.9%) is mainly related to demographic ageing and not to an increase of age-specific risks. The fraction of non-classifiable AML cases decreased over time (54.6% to 41.8%) but remained high in elderly patients (65–74 yrs: 44%; 75–84 yrs: 54.2%, 85 + yrs: 59.1%), suggesting less accurate diagnostics and reporting with increasing age. 5 yrs relative survival (RS) correlated with AML risk class (favorable: 61.7%-68.4%; adverse risk: 11.4%-21.9%) and age (< 65 yrs: 42.6–43.3%; 75–84 yrs: 2.0-3.0%), but improved only modestly overall (19.2% to 23.3%). Interestingly, we identified a significant improvement of RS in patients aged 65–74 yrs (5 yrs: 5.2% to 13.5%; p < 0.001). As surrogate for changes in management, we found an increase of allogeneic haematopoietic stem cell transplantations (1.4 to 7%) and clinical trial activities (25 to 29%) for elderly AML patients during the observation period. Our analysis indicates that recent progress made in management of elderly AML patients results in an improvement of survival on a population-based level in Switzerland and that therapeutic nihilism is not justifiable.

1. Introduction

Acute myeloid leukaemia (AML) is a rare and heterogeneous disorder arising from genetic lesions in the haematopoietic stem cell compartment. It is a highly malignant condition, characterized by proliferation of immature myeloid precursors and

https://doi.org/10.1016/j.canep.2017.11.008
Received 13 September 2017; Received in revised form 22 November 2017; Accepted 24 November 2017
1877-7821/ © 2017 Elsevier Ltd. All rights reserved.